Publication details
Studie EUROPA a ASCOT znovu přepisují léčbu
| Title in English | The EUROPA and ASCOT again change the treatment |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze & kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; dyslipidemia; perindopril; amlodipin; statin |
| Description | Fixed combination of two antihypertensive drugs increase the adherence to the treatment and lead to better compliance to the treatment. Data from two large clinical trials (ASCOT BPLA, ACCOMPLISH) show that a combination of an ACE inhibitor and long acting calcium blocker, dihydropyridine type are a preferred modality for antihypertensive treatment, leading to the decrease of mortality and morbidity. Data from EUROPA trial confirm the same for patients with ischemic heart disease. Data from primary preventive trial show a positive effect of statins, especiallly from ASCOT LLA - a combination of statin, ACE inhibitor and dihydropyridin (atorvastatin, perindopril, amlodipin). |